These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 9449120)
21. [Vaccine therapy of prostate cancer]. Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic vaccines for prostate cancer: a review of clinical data. Arlen PM; Gulley JL Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910 [TBL] [Abstract][Full Text] [Related]
23. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Tacken PJ; de Vries IJ; Torensma R; Figdor CG Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902 [TBL] [Abstract][Full Text] [Related]
31. Dendritic cell immunotherapy for the treatment of neoplastic disease. Decker WK; Xing D; Shpall EJ Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510 [TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Lin AM; Hershberg RM; Small EJ Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496 [TBL] [Abstract][Full Text] [Related]
33. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia. Dietz AB; Litzow MR; Gastineau DA; Vuk-Pavlović S Croat Med J; 2001 Aug; 42(4):428-35. PubMed ID: 11471194 [TBL] [Abstract][Full Text] [Related]
36. Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. Belldegrun A; Bander NH; Lerner SP; Wood DP; Pantuck AJ J Urol; 2001 Oct; 166(4):1316-21. PubMed ID: 11547065 [TBL] [Abstract][Full Text] [Related]
37. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Salgaller ML; Thurnher M; Bartsch G; Boynton AL; Murphy GP Cancer; 1999 Dec; 86(12):2674-83. PubMed ID: 10594863 [No Abstract] [Full Text] [Related]
39. [The possibility and limitations of cell therapy. 2) The current status and overview of tumor-immune cell therapy--T cell-dendritic cell therapy]. Kawakami Y Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1923-8. PubMed ID: 17929434 [No Abstract] [Full Text] [Related]
40. Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen? Karan D Immunotherapy; 2013 Sep; 5(9):907-10. PubMed ID: 23998723 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]